The GOLD (Global Initiative for Obstructive Chronic Lung Disease) initiative recognizes that people with Chronic Obstructive Pulmonary Disease (COPD) are among those most affected by COVID-19 and GOLD is working with the WHO (World Health Organization) to treat to minimize the impact of infection. GOLD strongly recommends that people with COPD follow the advice of
COVID-19 Technical guidance | Patient management Read More »
The Global Alpha 1 Foundation has answered the most frequently asked questions in the scientific and social environment. Refers to the direct relationship between COVID-19 and the Alpha-1 deficit. Click to further information. Read more
COVID-19 Frequently Asked Questions Read More »
A work published last month in the Journal of Clinical Medicine shows the “profound ignorance of rare respiratory diseases among pediatric professionals and medical students” in Spain. The article, in which several of the country’s leading specialists in Alpha-1 Antitrypsin Deficit (DAAT) have a prominent role, calls for “including relevant material in the Medicine study
The European alpha community celebrates for the first time in its history the European Alpha-1 Antitrypsin Deficit Day (European Alpha-1 Awareness Day), promoted by the international alliance of patients Alpha-1 Global with the support of the associations of the community countries. The commemoration is celebrated on April 25, 2020.
April 25, 2020: European Alpha-1 Antitrypsin Deficit Day Read More »
ALAT-Neumosur Symposium: COPD due to Alpha-1 Antitrypsin Deficiency. 11th ALAT Congress. Mexico City, June 27-30, 2018. Regional Meetings to update knowledge about the DAAT in collaboration with the Alfa-1 Spain Association. HU Virgen del Rocío. Seville, May 12, 2018. Regional Meetings to update knowledge about the DAAT in collaboration with the Alfa-1 Spain Association. HU
The AlfaCare program, “Care and Resources to live with the Alpha-1 Antitrypsin Deficit (AATD)” has taken place at the Torrecárdenas Hospital in Almería. It is a comprehensive program of accompaniment and personalized support, created in collaboration with the Association of Alfa-1 Spain, which offers training, emotional support and support to patients affected by AATD through
Alfacare Workshop Almería 2020 Read More »
Our center has started to include patients in the EARCO (European Alpha-1 Research Collaboration). EARCO is a pan-European network committed to promoting clinical research and education in alpha-1 antitrypsin deficiency (AATD). The core project is the Pan-European AATD Registry, a collaboration that will provide real-world longitudinal data for AATD patients. EARCO has a global vision to
EARCO (European Alpha-1 Research Collaboration) Read More »
Grifols launches AlphaID ™, its free oral test that allows the diagnosis of most of the genetic variants that cause alpha-1 antitrypsin deficiency (AATD). AlphaID ™ makes it easy for clinicians to diagnose AATD, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD). Read more
Grifols Launches AlphaID ™ Read More »
The meeting of the Committee of the Spanish Registry of Patients with Alpha-1 Antitrypsin Deficiency (REDAAT) took place in Lisbon within the framework of the “AATD Experts Forum Iberia, Alpha-1 antitrypsin: A look to the future”, held in Lisbon and which has brought together experts from Spain and Portugal. Dr. Casas has participated in the
AATD Experts Forum Iberia 2019 Read More »
This document, coordinated by Drs. Francisco Casas (Coordinator of the Andalusian Alpha-1 Center in Granada) and José Antonio Quintano (Spanish Society of Primary Care Physicians – SEMERGEN) have the following objectives: 1) to improve the knowledge of COPD by DAAT by Primary Care. 2) sensitize the family doctor about the importance of early diagnosis 3)
